Innova Biosciences Launches Range of Conjugated Antibodies
This new range includes antibodies conjugated to various enzymes, fluorescent dyes, and colloidal gold, for improved flexibility in experimental design.
Bioconjugation products and services provider, Innova Biosciences, has launched a range of conjugated antibodies, which leverages the company’s Lightning-Link and InnovaCoat bioconjugation technologies. This range includes antibodies conjugated to various enzymes, fluorescent dyes, and colloidal gold, for improved flexibility in experimental design.
The new range comprises 200 antibodies to nearly 30 different cardiac biomarkers, each available directly conjugated to 24 different enzymes, fluorescent dyes, or nanoparticles. Innova plans to expand the range into other key research areas in the near future.
In conjunction with the range, Innova has launched a new website that facilitates online ordering. The Antibody Conjugate Generator tool enables customers ordering from the new conjugated antibodies range to select any desired cardiac marker, antibody clone, and label. The website also provides resources and support materials.
More information about the new conjugated antibody range can be found at www.innovabiosciences.com/products/antibody-conjugates.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
